HAUGHEY THOMAS sold $162K of ANIP
HAUGHEY THOMAS sold 2,000 shares of ANI PHARMACEUTICALS INC (ANIP) at $80.88 ($0.16M total) on 2026-06-08 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the insider’s holdings (38,878 shares after sale) and confirms the transaction was executed under a pre-arranged 10b5-1 plan.
Market read
Primarily a sentiment/positioning datapoint; limited fundamental implications due to 10b5-1 pre-arrangement.
What to watch
Traders may still monitor whether multiple insiders sell outside 10b5-1 windows or whether there are concurrent operational/regulatory catalysts not mentioned here.
Background
The article is an SEC Form 4 insider transaction disclosure for ANI Pharmaceuticals.
Ticker impact
Director Thomas Haughey sold 2,000 shares of ANI Pharmaceuticals on a pre-arranged 10b5-1 plan at $80.88/share, per Form 4 filed June 10.
Low likelihood of sustained price impact; any reaction is likely muted and short-lived.
The filing is an SEC Form 4 insider transaction and explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No clear sector read-through from a single director’s 10b5-1 sale.
None indicated.
None indicated.
Counterpoint
Because the sale is pre-arranged, it could be viewed as compliance-driven rather than a negative view on the business, limiting downside follow-through.
Key entities
- issuerANI Pharmaceuticals Inc
Subject of the Form 4 insider sale disclosure.
- insiderHAUGHEY THOMAS
Director who sold 2,000 shares under a 10b5-1 plan.
